Macromolecular (pro) drugs in antiviral research

被引:28
|
作者
Smith, Anton A. A. [1 ]
Kryger, Mille B. L. [1 ,2 ]
Wohl, Benjamin M. [1 ,2 ]
Ruiz-Sanchis, Pau [1 ]
Zuwala, Kaja [3 ]
Tolstrup, Martin [3 ]
Zelikin, Alexander N. [1 ,2 ]
机构
[1] Aarhus Univ, Dept Chem, DK-8000 Aarhus, Denmark
[2] Aarhus Univ, iNANO Interdisciplinary Nanosci Ctr, DK-8000 Aarhus, Denmark
[3] Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; STRONGLY INHIBIT AGGLUTINATION; LIVING RADICAL POLYMERIZATION; ANTI-HIV ACTIVITY; POLY-L-LYSINE; INFLUENZA-VIRUS; IN-VITRO; ENVELOPE GLYCOPROTEIN; DEXTRAN SULFATE;
D O I
10.1039/c4py00624k
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
Macromolecular (pro) drugs are a sub-discipline of medicinal and polymer chemistries aiming to optimize the delivery of drugs to their site of action. In recent decades, this field of science has undergone a tremendous development, with the soundest achievements registered in the delivery of anticancer drugs. Surprisingly, the development of these tools for applications in antiviral treatment lags significantly behind -despite the fact that the first in vivo successes of polymers in fighting viruses were reported half a century ago. Furthermore, the unique scope and utility of polymers in antiviral research is that macromolecules themselves exhibit highly potent activity against diverse viruses. Herein, in an attempt to revive the research interest in this field, we aim to provide an overview of successes (and failures) of polymers as antiviral agents and macromolecular prodrugs. Specifically, we discuss inhibition of the entry of the virus into mammalian cells by polymers, give an overview of the synthetic schemes applied for the conjugation of drugs to carrier polymers, and also present guidance with regard to potential reporter systems which can be used for the characterization of novel drug delivery systems in virus-free cell cultures.
引用
收藏
页码:6407 / 6425
页数:19
相关论文
共 50 条
  • [21] ANTIVIRAL DRUGS 1983
    DOUGLAS, RG
    MEDICAL CLINICS OF NORTH AMERICA, 1983, 67 (05) : 1163 - 1172
  • [22] AFTER PRO-DRUGS - MUTUAL PRO-DRUGS
    WISE, R
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1981, 7 (05) : 503 - 504
  • [23] Antiviral Drugs for Influenza
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2009, 51 (1325): : 89 - 92
  • [24] ANTIVIRAL DRUGS IN PEDIATRICS
    BALFOUR, HH
    ENGLUND, JA
    AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1989, 143 (11): : 1307 - 1316
  • [25] ANTIVIRAL DRUGS TODAY
    HARKNESS, JL
    ATKINSON, K
    MEDICAL JOURNAL OF AUSTRALIA, 1983, 1 (13) : 597 - 598
  • [26] COMBINATION OF ANTIVIRAL DRUGS
    SENNEVILLE, E
    BEUSCART, C
    MOUTON, Y
    MEDECINE ET MALADIES INFECTIEUSES, 1994, 24 (8-9): : 814 - 821
  • [27] Antiviral Drugs for EBV
    Pagano, Joseph S.
    Whitehurst, Christopher B.
    Andrei, Graciela
    CANCERS, 2018, 10 (06)
  • [28] Antiviral Drugs for Influenza
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1589): : 1 - 4
  • [29] Antiviral Drugs in Influenza
    Swierczynska, Magdalena
    Mirowska-Guzel, Dagmara M.
    Pindelska, Edyta
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (05)
  • [30] Pharmacogenomics and antiviral drugs
    Pirmohamed, M
    CLINICA CHIMICA ACTA, 2005, 355 : S22 - S22